Pingshuan Dong

机构：Tianjin Medical University General Hospital, First Affiliated Hospital of Henan University of Science and Technology · ORCID：0000-0002-9862-7367

发表论文 88 篇 · 总被引 1112 次 · h-index 17

代表论文

• Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2023 · The Lancet Diabetes & Endocrinology · 被引 41)
• Performance of Management Strategies With Class I Recommendations Among Patients Hospitalized With ST-Segment Elevation Myocardial Infarction in China (2022 · JAMA Cardiology · 被引 32)
• Puerarin protects cardiomyocytes from ischemia–reperfusion injury by upregulating LncRNA ANRIL and inhibiting autophagy (2021 · Cell and Tissue Research · 被引 31)
• Fluorescent Magnetic Iron Oxide NanoparticleEncapsulated Protein Hydrogel Against Doxorubicin-Associated Cardiotoxicity and for Enhanced Cardiomyocyte Survival (2020 · Journal of Biomedical Nanotechnology · 被引 14)
• Treatment delay and reperfusion management of acute ST-segment elevation myocardial infarction: analysis of the China STEMI Care Project Phase 1 (2020 · QJM · 被引 11)
• Impacts of air pollutions on cardiovascular and cerebrovascular diseases through inflammation: a comprehensive analysis of one million Chinese and half million UK individuals (2025 · Journal of Translational Medicine · 被引 9)